| Date Filed | Type | Description |
| 10/04/2023 |
4
| Huber Martin H. Jr. (President, CEO) has filed a Form 4 on Mersana Therapeutics, Inc.|
Txns:
| Granted 9,102 options to buy
@ $1.26, valued at
$11.5k
|
|
| 10/04/2023 |
4
| Dere Willard H (Director) has filed a Form 4 on Mersana Therapeutics, Inc.|
Txns:
| Granted 11,011 shares
@ $0 |
|
| 10/04/2023 |
4
| Hege Kristen (Director) has filed a Form 4 on Mersana Therapeutics, Inc.|
Txns:
| Granted 9,523 options to buy
@ $1.26, valued at
$12k
|
|
| 10/04/2023 |
4
| Alleva Lawrence M (Director) has filed a Form 4 on Mersana Therapeutics, Inc.|
Txns:
| Granted 14,047 options to buy
@ $1.26, valued at
$17.7k
|
|
| 10/04/2023 |
4
| MOTT DAVID M (Director) has filed a Form 4 on Mersana Therapeutics, Inc.|
Txns:
| Granted 15,873 shares
@ $0 |
|
| 08/18/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/08/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/08/2023 |
8-K
| Quarterly results |
| 08/07/2023 |
SC 13G
| Venrock Healthcare Capital Partners III, L.P. reports a 8.5% stake in Mersana Therapeutics, Inc. |
| 07/31/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 07/27/2023 |
SC 13G
| EcoR1 Capital, LLC reports a 16.9% stake in Mersana Therapeutics, Inc. |
| 07/27/2023 |
8-K
| Results of Operations and Financial Condition, Cost Associated with Exit or Disposal Activities, Regulation FD Disclosure, Ot... |
| 07/06/2023 |
4
| Alleva Lawrence M (Director) has filed a Form 4 on Mersana Therapeutics, Inc.|
Txns:
| Granted 5,391 options to buy
@ $3.42, valued at
$18.4k
|
|
| 07/06/2023 |
4
| Huber Martin H. Jr. (Director) has filed a Form 4 on Mersana Therapeutics, Inc.|
Txns:
| Granted 4,477 options to buy
@ $3.42, valued at
$15.3k
|
|
| 07/06/2023 |
4
| Hege Kristen (Director) has filed a Form 4 on Mersana Therapeutics, Inc.|
Txns:
| Granted 3,654 options to buy
@ $3.42, valued at
$12.5k
|
|
| 07/06/2023 |
4
| Dere Willard H (Director) has filed a Form 4 on Mersana Therapeutics, Inc.|
Txns:
| Granted 4,217 shares
@ $0 |
|
| 07/06/2023 |
4
| MOTT DAVID M (Director) has filed a Form 4 on Mersana Therapeutics, Inc.|
Txns:
| Granted 6,079 shares
@ $0 |
|
| 06/12/2023 |
4
| Hack Andrew A. F. (Director) has filed a Form 4 on Mersana Therapeutics, Inc.|
Txns:
| Granted 14,467 shares
@ $0
Granted 18,355 options to buy
@ $8.64, valued at
$158.6k
|
|
| 06/12/2023 |
4
| Diaz Allene M. (Director) has filed a Form 4 on Mersana Therapeutics, Inc.|
Txns:
| Granted 14,467 shares
@ $0
Granted 18,355 options to buy
@ $8.64, valued at
$158.6k
|
|
| 06/12/2023 |
4
| Hege Kristen (Director) has filed a Form 4 on Mersana Therapeutics, Inc.|
Txns:
| Granted 14,467 shares
@ $0
Granted 18,355 options to buy
@ $8.64, valued at
$158.6k
|
|
| 06/12/2023 |
4
| Huber Martin H. Jr. (Director) has filed a Form 4 on Mersana Therapeutics, Inc.|
Txns:
| Granted 14,467 shares
@ $0
Granted 18,355 options to buy
@ $8.64, valued at
$158.6k
|
|
| 06/12/2023 |
4
| MOTT DAVID M (Director) has filed a Form 4 on Mersana Therapeutics, Inc.|
Txns:
| Granted 14,467 shares
@ $0
Granted 18,355 options to buy
@ $8.64, valued at
$158.6k
|
|
| 06/12/2023 |
4
| Alleva Lawrence M (Director) has filed a Form 4 on Mersana Therapeutics, Inc.|
Txns:
| Granted 14,467 shares
@ $0
Granted 18,355 options to buy
@ $8.64, valued at
$158.6k
|
|
| 06/12/2023 |
4
| Dere Willard H (Director) has filed a Form 4 on Mersana Therapeutics, Inc.|
Txns:
| Granted 14,467 shares
@ $0
Granted 18,355 options to buy
@ $8.64, valued at
$158.6k
|
|
| 06/09/2023 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders... |
| 05/09/2023 |
S-3ASR
| Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers: |
| 05/09/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/09/2023 |
8-K
| Quarterly results |
| 04/28/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/28/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/28/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/28/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/14/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 04/05/2023 |
4
| Hege Kristen (Director) has filed a Form 4 on Mersana Therapeutics, Inc.|
Txns:
| Granted 3,451 options to buy
@ $4.25, valued at
$14.7k
|
|
|